| Dr Waleed Lutfi Lutfiyya, MD | |
|
9900 Se Sunnyside Rd, Sunnybrook Medical Office Building, Clackamas, OR 97015-9777 | |
| (503) 890-2833 | |
| Not Available |
| Full Name | Dr Waleed Lutfi Lutfiyya |
|---|---|
| Gender | Male |
| Speciality | Colorectal Surgery (proctology) |
| Experience | 23 Years |
| Location | 9900 Se Sunnyside Rd, Clackamas, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770652752 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kaiser Foundation Hospital - Westside | Hillsboro, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kaiser Foundation Health Plan Of The Northwest | 5799688230 | 1482 |
News Archive
Researchers have identified a new cancer gene - one that is common to many cancers and affects the most basic regulation of our genes.
While it may not shock you to learn that children born with disorders of sex development (DSD) face challenges, Concordia University researchers have confirmed that these go far beyond the physical.
A team of researchers has found that doses of bilirubin help provide suppression of the immune response following islet transplantation in mouse models.
Meetings begin this week to determine what benefits insurers must cover under the new health law. The resulting regulation will be just one of the ways in which the new health law will change the health care landscape.
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML).
› Verified 1 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Northwest |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184786527 PECOS PAC ID: 5799688230 Enrollment ID: O20040130000799 |
News Archive
Researchers have identified a new cancer gene - one that is common to many cancers and affects the most basic regulation of our genes.
While it may not shock you to learn that children born with disorders of sex development (DSD) face challenges, Concordia University researchers have confirmed that these go far beyond the physical.
A team of researchers has found that doses of bilirubin help provide suppression of the immune response following islet transplantation in mouse models.
Meetings begin this week to determine what benefits insurers must cover under the new health law. The resulting regulation will be just one of the ways in which the new health law will change the health care landscape.
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Waleed Lutfi Lutfiyya, MD 9900 Se Sunnyside Rd, Sunnybrook Medical Office Building, Clackamas, OR 97015-9777 Ph: (503) 890-2833 | Dr Waleed Lutfi Lutfiyya, MD 9900 Se Sunnyside Rd, Sunnybrook Medical Office Building, Clackamas, OR 97015-9777 Ph: (503) 890-2833 |
News Archive
Researchers have identified a new cancer gene - one that is common to many cancers and affects the most basic regulation of our genes.
While it may not shock you to learn that children born with disorders of sex development (DSD) face challenges, Concordia University researchers have confirmed that these go far beyond the physical.
A team of researchers has found that doses of bilirubin help provide suppression of the immune response following islet transplantation in mouse models.
Meetings begin this week to determine what benefits insurers must cover under the new health law. The resulting regulation will be just one of the ways in which the new health law will change the health care landscape.
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML).
› Verified 1 days ago
Dr. James W Dennis, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 9900 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-786-8435 | |
Mary Elizabeth Giswold, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 10100 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-571-3099 | |
Daniel Alan Ladizinsky, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 9900 Se Sunnyside Rd, Kasier Permanente Sunnybrook Medical Office, Clackamas, OR 97015 Phone: 503-571-3162 Fax: 503-571-3069 | |
Dr. Nicholas Petrochko Jr., M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 9900 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-652-2880 Fax: 503-571-8984 | |
Dr. Robert Ludemann, M.D. PH.D. Surgery Medicare: Medicare Enrolled Practice Location: 10100 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-571-3066 Fax: 503-571-3069 | |
James A Schwarz, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 10100 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-786-8435 | |
Charles Youngjoong Kim, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 9900 Se Sunnyside Rd, Sunnybrook Medical Office, Clackamas, OR 97015 Phone: 503-786-8435 |